Clinical Trials Logo
  1. Home
  2. HCC
  3. NCT04069416

Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria

Hcc Clinical Trial

Official title:
Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria in High Prevalence Young HCC Patients Country.

Clinical Trial Summary

The present study aims to evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients.

Clinical Trial Description

Introduction:

HEPATOCELLULAR CARCINOMA (HCC) is the second leading cause of cancer mortality worldwide. Living donor liver transplantation (LDLT) for HCC patients has emerged as a rewarding therapy for a cure and a successful alternative where a Deceased donor liver transplantation (DDLT) program is lacking. Therefore, trials for careful expansion to Milan criteria have been adopted.

Aim of the study:

To evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04069416
Study type Observational
Source Ain Shams University
Contact
Status Completed
Phase
Start date January 2004
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05458115 - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Enrolling by invitation NCT02256514 - Open Label Trial of Immunotherapy for Advanced Liver Cancer Phase 2
Not yet recruiting NCT06434480 - SBRT in HCC With Oligoprogression on Atezo-Bev N/A
Completed NCT04542837 - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT05025592 - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed NCT04172506 - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06024252 - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Not yet recruiting NCT05840133 - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Terminated NCT02785874 - Statin With Palliative Therapy for HCC N/A
Not yet recruiting NCT02715492 - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Phase 3
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Not yet recruiting NCT06069947 - SALT for Liver Cirrhosis With HCC N/A
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Suspended NCT02935478 - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation N/A
Recruiting NCT05592171 - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05544253 - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC Phase 2/Phase 3
Recruiting NCT06184152 - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed NCT02675920 - A Study of HCC High Risk Group Using Two Surveillance Tools